Document And Entity Information
Document And Entity Information - USD ($) | Dec. 31, 2022 | Mar. 28, 2023 | Jun. 30, 2022 |
Document Information [Line Items] | |||
Entity, Registrant Name | SAB BIOTHERAPEUTICS, INC. | ||
Document, Type | 10-K/A | ||
Document, Annual Report | true | ||
Document, Period End Date | Dec. 31, 2022 | ||
Current Fiscal Year End Date | --12-31 | ||
Document, Fiscal Period Focus | FY | ||
Document, Fiscal Year Focus | 2021 | ||
Document, Transition Report | false | ||
Entity, File Number | 001-39871 | ||
Entity, Incorporation, State or Country Code | DE | ||
Entity, Tax Identification Number | 85-3899721 | ||
Entity, Address, Address Line One | 2100 East 54th Street North | ||
Entity, Address, City or Town | Sioux Falls | ||
Entity, Address, State or Province | SD | ||
Entity, Address, Postal Zip Code | 57104 | ||
City Area Code | 605 | ||
Local Phone Number | 679-6980 | ||
Entity, Well-known Seasoned Issuer | No | ||
Entity, Voluntary Filers | No | ||
Entity, Current Reporting Status | Yes | ||
Entity, Interactive Data, Current | Yes | ||
Entity, Filer Category | Non-accelerated Filer | ||
Entity, Small Business | true | ||
Entity, Emerging Growth Company | true | ||
Entity, Ex Transition Period | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity, Shell Company | false | ||
Entity, Public Float | $ 32,737,282 | ||
Entity, Common Stock Shares, Outstanding | 50,397,762 | ||
Auditor Firm ID | 199 | ||
Auditor Name | Mayer Hoffman McCann P.C. | ||
Auditor Location | San Diego, California, United States | ||
Amendment Description | The purpose of this Amendment No. 1 to the Annual Report on Form 10-K (the “Amendment”) is to amend the cover page of the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2023, to reflect the correct aggregate market value of the voting and non-voting common equity held by non-affiliates of SAB Biotherapeutics, Inc. (the “Company”), as of June 30, 2022. Except as described above, no other changes have been made to the Annual Report and this Amendment does not reflect events occurring after the filing of the Annual Report, and no attempt has been made in this Amendment to modify or update other disclosures as presented in the Annual Report. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Amendment also contains new certifications of the Company’s principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements are included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 or 308 of Regulation S-K promulgated by the SEC under the Exchange Act, paragraphs 3, 4 and 5 of the Section 302 certifications have been omitted. In addition, because no financial statements are included in this Amendment, new certifications of the Company’s principal executive officers and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with this Amendment. This Amendment also contains an updated consent of the Company’s independent registered public accounting firm, included as Exhibit 23.1. | ||
Amendment Flag | true | ||
Entity, Central Index Key | 0001833214 | ||
CommonStock00001ParValuePerShare Custom [Member] | |||
Document Information [Line Items] | |||
Title of 12(b) Security | Common stock, $0.0001 par value per share | ||
Trading Symbol | SABS | ||
Security Exchange Name | NASDAQ | ||
Warrants Custom [Member] | |||
Document Information [Line Items] | |||
Title of 12(b) Security | Warrants | ||
Trading Symbol | SABSW | ||
Security Exchange Name | NASDAQ |